Literature DB >> 21743439

Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.

Pelagia Deriziotis1, Ralph André, David M Smith, Rob Goold, Kerri J Kinghorn, Mark Kristiansen, James A Nathan, Rina Rosenzweig, Dasha Krutauz, Michael H Glickman, John Collinge, Alfred L Goldberg, Sarah J Tabrizi.   

Abstract

Prion diseases are associated with the conversion of cellular prion protein (PrP(C)) to toxic β-sheet isoforms (PrP(Sc)), which are reported to inhibit the ubiquitin-proteasome system (UPS). Accordingly, UPS substrates accumulate in prion-infected mouse brains, suggesting impairment of the 26S proteasome. A direct interaction between its 20S core particle and PrP isoforms was demonstrated by immunoprecipitation. β-PrP aggregates associated with the 20S particle, but did not impede binding of the PA26 complex, suggesting that the aggregates do not bind to its ends. Aggregated β-PrP reduced the 20S proteasome's basal peptidase activity, and the enhanced activity induced by C-terminal peptides from the 19S ATPases or by the 19S regulator itself, including when stimulated by polyubiquitin conjugates. However, the 20S proteasome was not inhibited when the gate in the α-ring was open due to a truncation mutation or by association with PA26/PA28. These PrP aggregates inhibit by stabilising the closed conformation of the substrate entry channel. A similar inhibition of substrate entry into the proteasome may occur in other neurodegenerative diseases where misfolded β-sheet-rich proteins accumulate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21743439      PMCID: PMC3160194          DOI: 10.1038/emboj.2011.224

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  60 in total

1.  Pathway complexity of prion protein assembly into amyloid.

Authors:  Ilia V Baskakov; Giuseppe Legname; Michael A Baldwin; Stanley B Prusiner; Fred E Cohen
Journal:  J Biol Chem       Date:  2002-03-23       Impact factor: 5.157

Review 2.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

Authors:  Michael H Glickman; Aaron Ciechanover
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

3.  Proteasome disassembly and downregulation is correlated with viability during stationary phase.

Authors:  Monika Bajorek; Daniel Finley; Michael H Glickman
Journal:  Curr Biol       Date:  2003-07-01       Impact factor: 10.834

4.  Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions.

Authors:  Yadong Yu; David M Smith; Ho Min Kim; Victor Rodriguez; Alfred L Goldberg; Yifan Cheng
Journal:  EMBO J       Date:  2009-12-17       Impact factor: 11.598

5.  Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.

Authors:  Zaira Ortega; Miguel Díaz-Hernández; Christa J Maynard; Félix Hernández; Nico P Dantuma; José J Lucas
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

6.  Binding of amyloid beta protein to the 20 S proteasome.

Authors:  L Gregori; J F Hainfeld; M N Simon; D Goldgaber
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

7.  Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening.

Authors:  Andreas Peth; Henrike C Besche; Alfred L Goldberg
Journal:  Mol Cell       Date:  2009-12-11       Impact factor: 17.970

8.  Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins.

Authors:  Henrike C Besche; Wilhelm Haas; Steven P Gygi; Alfred L Goldberg
Journal:  Biochemistry       Date:  2009-03-24       Impact factor: 3.162

9.  Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction.

Authors:  Elena Quaglio; Elena Restelli; Anna Garofoli; Sara Dossena; Ada De Luigi; Luigina Tagliavacca; Daniele Imperiale; Antonio Migheli; Mario Salmona; Roberto Sitia; Gianluigi Forloni; Roberto Chiesa
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Molecular distinction between pathogenic and infectious properties of the prion protein.

Authors:  Roberto Chiesa; Pedro Piccardo; Elena Quaglio; Bettina Drisaldi; San Ling Si-Hoe; Masaki Takao; Bernardino Ghetti; David A Harris
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  54 in total

1.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

2.  Tau toxicity feeds forward in frontotemporal dementia.

Authors:  David C Rubinsztein
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

Review 3.  Prions and the potential transmissibility of protein misfolding diseases.

Authors:  Allison Kraus; Bradley R Groveman; Byron Caughey
Journal:  Annu Rev Microbiol       Date:  2013-06-28       Impact factor: 15.500

Review 4.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

Review 5.  Lysosomal Quality Control in Prion Diseases.

Authors:  Priyanka Majumder; Oishee Chakrabarti
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 6.  Regulating protein breakdown through proteasome phosphorylation.

Authors:  Jordan J S VerPlank; Alfred L Goldberg
Journal:  Biochem J       Date:  2017-09-24       Impact factor: 3.857

7.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 8.  Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.

Authors:  Natura Myeku; Karen E Duff
Journal:  Trends Mol Med       Date:  2017-12-09       Impact factor: 11.951

Review 9.  Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.

Authors:  Steven H Graham; Hao Liu
Journal:  Ageing Res Rev       Date:  2016-10-01       Impact factor: 10.895

Review 10.  The Logic of the 26S Proteasome.

Authors:  Galen Andrew Collins; Alfred L Goldberg
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.